Media Coverage

Obesity, complexity, and the lab: What 2025 taught us, and what comes next

Hvivo appoints veteran pharma executive to board

Unlocking the future of obesity treatment

MSD to acquire Cidara after positive phase 2b trial results

Cidara and hVIVO report positive results in flu prevention study

A cash-rich stock with the foundations for growth

SMALL CAP IDEA: 'Flu Camp' rapid drug trial firm slashes big pharma costs

This lowly rated research stock is a real bargain

MARKET REPORT: Bad news for WPP as advertising giant warns of a dire year ahead

Hvivo acquires clinical storage specialist

Cathal Friel-chaired Hvivo acquires bio storage group Cryostore in €3.9 million deal

Hvivo secures £2m deal with a new biopharmaceutical client

HVIVO: Research firm announces final stage of study on cold-like virus human metapneumovirus

Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO

hVIVO acquires Germany’s CRS for ‘significant European foothold’

Inhalon launches human challenge trial for RSV treatment

hVIVO plans challenge trial for RSV antiviral candidate

BRIEF—hVIVO acquires two German clinical research units

Hvivo reports record revenues and the acquisition of a German research firm

hVivo expands with acquisition of German clinical trial units

Clinical trials group Hvivo expands into Germany with €10m acquisition

Hvivo’s shares rise 8.5% as it signs world’s first ‘Phase 3’ human trial for whooping cough

Hvivo to tackle whooping cough with its biggest ever human trial

Hvivo secures £2.7m contract, marking largest deal to date

Is HMPV in the UK and how worried should we be? Experts weigh in

Is this the start of a new pandemic? As hMPV cases rise, everything you need to know about the 'mystery' illness

Urgent HMPV warning as virus cases double in Britain in under a month

Could the mystery China hMPV virus outbreak trigger a pandemic? Experts give verdicts

HPMV cases DOUBLE in Britain with experts urging China to disclose vital information on outbreak

Should Britain be worried about the virus spreading in China?

UK experts urge China to reveal crucial details of HPMV outbreak - as cases DOUBLE in Britain

Patients who've been struck down by virus ravaging China describe horrific symptoms: 'Worst I've ever felt'

HMPV outbreak: How it's SOARING in the 'super-spreader' under 5 year-olds...who are most at risk of serious illness

HMPV outbreak: UK experts call for more information on virus in China as London scientists play down risk

CEO update - 16 December 2024 | BIA

Hvivo signs €14 million contract with ‘global pharma client’ and confirms guidance

hVIVO shares rise on contract win and reaffirmed revenue guidance

Would you volunteer to get yourself infected with flu in Canary Wharf?

Eight AIM shares ripe for a rally as Budget concerns subside

How to revive the UK's small-cap sector

hVIVO is in pole position to capitalise on increasing interest in human challenge trials

hVIVO – Institutional Holdings Building Up After This Week’s Strong First Half Report

hVIVO hails ‘record’ half-year revenue, as profit soars 70% higher

hVIVO has foundations for strong growth

Strong first half for Hvivo puts company on track to meet full year guidance

Clinical trial specialist hVivo's H1 revenues jump by 30%

Irish-founded Hvivo posts record revenue with 30 per cent jump in H1

Earnings rise 68pc at pharmaceutical services firm Hvivo

hVIVO earnings up by 67.6% in first half

hVIVO – Foundations Laid For Strong Performance In The Months And Years Ahead, Institutions Building Up Stakes Ahead Of Interims

Inside Canary Wharf’s infectious disease testing facility

‘Fail fast. Succeed fast.’ Inside Hvivo’s new Canary Wharf human trials facility

HVIVO Reports 30% Increase In H1 Revenue Following Canary Wharf Move

‘Search mode’: Human challenge trial company looks to buy small CROs

hVIVO reports 31% revenue jump; relocation to improve efficiencies

MARKET REPORT: Rout wipes £260 billion off trio of US tech titans

Research firm Hvivo records 31pc jump in revenues in first half

Hvivo reports 30% revenue increase following record number of volunteer inoculations

Hvivo revenue reaches record in fist half of 2024

hVIVO gathers momentum as revenue jumps 30%

hVIVO on the upgrade again

Is it worth £7000 to be infected with a disease and go into lockdown?

Expert View: Sage, Craneware, Quilter, Sainsbury’s, Hvivo

Hvivo signs largest field study contract to date

Research firm hVivo to begin study into Omicron vaccine

Hvivo seals €2.9m contract for Covid-19 characterisation study

Hvivo has strong upside potential – even using conservative targets

Big Pharma Warms To HVIVO Human Challenge Clinical Trials

Increased demand boosts revenues at hVIVO as it eyes acquisitions

Earnings rise 44pc at pharmaceutical services firm hVIVO

hVIVO reports higher profits and revenues for 2023

hVIVO on track to hit target as it records revenue high in 2023

The hunt for good-value UK stocks

Private Investor's Diary: Four new companies for my portfolio

Business is booming at hVIVO

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

hVIVO's 2023 revenues rise by 15.5%

MARKET REPORT: Profit warning hammers shares in Speedy Hire

Investors hope Auction Technology Group will go under the hammer

hVIVO shares surge as revenue jumps, regular dividends planned in 2024

Life sciences firm hVIVO has record year as Canary Wharf site set for completion

Cathal Friel’s Hvivo plans cash return for investors as sales are forecast to hit £100m by 2028

Hvivo raises revenue targets as business continues to grow

Top marks again for high-flying M&S

MARKET REPORT: Shares in Marks & Spencer make a sparkling start to 2024

Hvivo signs €7.3m contract to test cold virus treatment

Hvivo signs €7.3m contract to test common cold treatment

HVIVO Signs €7.3m Testing Contract With Biotechnology Client

Irish-listed Hvivo signs €7.3m contract with biotechnology firm

Share tips of the year: from cruises to pet shops

MIDAS SHARE TIPS: From drug trials to M&S, how our top ideas beat the market

Volution wins fans as strong demand blows it higher

Irish-listed hVIVO signs €19.5m contract with pharma client to test RSV antiviral drug candidate

hVIVO wins new RSV testing contract amid strong trading performance, shares jump

British CRO hVIVO reels in £16.8M clinical trial deal for RSV drug

Chemring has to combat US defence order delays

Another upgrade makes this takeover target a buy

hVIVO raises 2023 revenue view on demand for respiratory therapy testings

Hvivo raises full year sales and earnings guidance after “excellent” start to 2023

Pharma services company Hvivo delivers record revenues in first half

hVIVO reports surge in half year revenues as HCTs rise

hVIVO featured on pages 54-56 of the digital magazine

Canary Wharf move means expansion for drug trials operator

Hvivo to move to larger “state-of-the-art” facility in London

Irish-listed pharma company Hvivo plans larger London facility to meet demand

Hvivo announces plans for bigger facility on back of ‘growing orderbook’

New clinical trial hub to open in Canary Wharf as demand for life sciences space heats up

MARKET REPORT: Blue-chips bounce as investors are buoyed by China stimulus and a slowdown in shop price rises in the UK

This ex-penny stock just paid its first ever dividend. Here’s how much

Ocado hits the heights as naysayers eat humble pie

Pharma services firm Hvivo shares jump 5% as orderbook grows

Human drug trial contracts drive 52% jump in revenue at Hvivo

Hvivo reports double-digit sales and profit growth for the first half of the year

A £13mn deal adds to hVIVO's record order book

Hvivo scores £13.1m contract to test influenza B vaccine

Irish-listed pharma company hVIVO signs €15.2m contract for development of flu challenge model

Tackling the most important virus that no one has heard of

Profit from this forecast-smashing update

Irish-listed pharma company Hvivo hails record year with 30pc revenue growth

Hvivo sees revenue jump 30% to £50.6 million on back of bigger contracts

Positive results from hVIVO study of Cidara flu candidate

Volunteers were purposefully infected with COVID-19. Was it worth it?

CRO hVIVO inks $8.2M deal to test RSV drug in human challenge trial

hVIVO signs £6.8m RSV human challenge contract with APAC client

Irish-founded hVIVO lands €7.5m contract to test vaccines

hVIVO signs €7.6m contract for trials of RSV treatment

hVIVO signs GBP6.8 million deal to test RSV antiviral drug candidate

hVIVO expecting record year; 2023 orderbook soars by 65% against 2022

hVIVO’s consultancy division Venn lands €3.2m pharma contract

hVIVO wins contract; Dev Clever cancels shares

COVID-19 vaccines: From nasal drops to a redesign, what 2023 could have in store

Profit from this fast-growing contract research business

Joanne Hart discusses picks for 2023 which include: GlobalData, hVIVO and Harland & Wolff

Grocers’ shares are pick of an attractive bunch

MARKET REPORT: London stock market edges higher despite recession fears and a sharp slump in commodity prices

hVIVO shares rise on new £5.2M contract

hVIVO inks £5.2m contract with biotechnology group

hVIVO Secures €5.9m Contract For Cold Virus Vaccine Trials

hVIVO lands £5.2m contract with Asia-Pacific biotech to test RSV vaccine

hVIVO inks €5.9m contract with Asia-Pacific biotech to test vaccine

Mo Khan CEO of HVIVO, 2022 in review

‘Way too many people worry too much about big cars and fancy houses’ – Cathal Friel

Human Clinical Trials: A Tool in the Fight Against Infectious Diseases

Mo Khan of hVIVO discusses their £13.6m contract with US-based biopharmaceutical client

Open Orphan announces experienced chartered accountant as new CFO

Stephen Pinkerton new CFO of Open Orphan discusses his experience and expectations

Open Orphan appoints Stephen Pinkerton as chief financial officer

Open Orphan reiterates £50m profit guidance, announces plans to rebrand as hVIVO

Liz Truss’ government must not keep science on the backburner, urges hVIVO CEO

Open Orphan rebrands to hVIVO as it focuses on human challenge business

Rise to the challenge: hVIVO says 3rd virus challenge contract is sign of growing demand

Would YOU deliberately get infected with flu for £3,250? Two-week drug trial will see healthy adults put up in a plush hotel where they can WFH, binge Netflix and play PS4

Open Orphan inks £10.4M deal to produce new H1N1 challenge virus

Open Orphan signs £10.4 million contract with global pharma client

£10.4m full-service contract signed with existing Big Pharma client

Renewable energy supplies bright spot for the markets

Open Orphan subsidiary to trial influenza antiviral for Big Pharma firm in £10m deal

Open Orphan subsidiary signs €12.3m deal with large pharma group

Pnuemagen embarks on phase 2 proof of concept influenza study

Open Orphan to commence influenza human challenge study

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

Open Orphan subsidiary working on world’s first Omicron challenge model

Vaxart signs pact with hVIVO to help develop oral COVID-19 vaccine pill

Green investment house still looking off-colour

Why some people still haven’t gotten Covid

Some people seem unable to catch COVID, scientists are trying to figure out why

Why do some people seem unable to catch COVID? Scientists are looking for answers.

Daily COVID Tracker: Brazil eases restrictions for international travellers

Doctor Explains Four Reasons Why Some People Don’t Get Covid

Deliberate infection trial finds COVID symptoms don’t indicate viral shedding

Open Orphan says Covid infection study may accelerate new vaccines

Open Orphan subsidiary signs €6m contract for respiratory study

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Open Orphan appoints Yamin Khan as new chief executive

Open Orphan names Khan as new CEO

Potential RSV vaccine achieves regulatory step in US

IN BRIEF: Positive results from Open Orphan human challenge study

Covid-19 news: US army discharges unvaccinated soldiers

Scientists deliberately gave people COVID — here’s what they learnt

Covid sufferers become infectious quicker than first thought, study shows

World-first COVID-19 human challenge trial

‘Human challenge’ Covid trial gives new insight into virus

Trial deliberately infecting young adults with Covid found to be safe

British COVID trial deliberately infecting young adults found to be safe

Covid symptoms appear much more quickly than previously thought – study

Covid infection takes hold in just 42 hours, pioneering London study shows

U.K. Covid Study on Healthy People Was Safe, Researchers Say

British Covid trial deliberately infecting young adults found to be safe

World-first COVID-19 human challenge trial found to be safe for young adults

SARS-CoV-2 Human Challenge Study Provides Infection Insights

British trial deliberately infecting young adults with COVID found to be safe

World’s first COVID human challenge trial found to be safe in young adults

Omicron and Long COVID: What We Know So Far